DEF: VSee Health Seeks Shareholder Approval for Private Placement

VSee Health, Inc. is holding a special meeting to seek stockholder approval for the issuance of common stock related to a recent private placement, as required by Nasdaq listing rules.

Summary

• A Special Meeting of Stockholders will be held on March 2, 2026, at 2:30 P.M. Eastern Time, via live webcast.
• Stockholders will vote on Proposal No. 1, the Private Placement Proposal, to approve the issuance of common stock to certain warrant holders in accordance with Nasdaq Listing Rule 5635(d).
• Stockholders will also vote on Proposal No. 2, the Adjournment Proposal, to approve adjourning the meeting if necessary to solicit further proxies.
• The Private Offering, which closed on December 1, 2025, involved the sale of 9,836,065 shares of common stock (or pre-funded warrants) and accompanying common warrants to purchase up to 19,672,130 shares of common stock to a single institutional investor.
• The private placement generated approximately $6 million in gross proceeds for the company.
• The purchase price per share (or pre-funded warrant) and accompanying warrants was $0.61, with the warrants exercisable at $0.61 per share.
• The Board of Directors unanimously recommends that stockholders vote FOR both the Private Placement Proposal and the Adjournment Proposal.
• As of the Record Date, February 2, 2026, there were 40,230,845 shares of Common Stock and 1,586 shares of Preferred Stock (entitled to 158,600 votes) outstanding.
• A quorum for the Special Meeting requires the presence, in person or by proxy, of holders representing one-third (33.33%) of the voting power, which is 13,408,941 votes.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as the company successfully raised capital, but the need for stockholder approval and potential future dilution from warrant exercise introduce some uncertainty.

Positives

• Successfully completed a private placement on December 1, 2025, raising approximately $6 million in gross proceeds, strengthening the company's financial position.
• The Board of Directors unanimously recommends approval of both proposals, indicating strong internal alignment and confidence in the transaction.
• Compliance with Nasdaq Listing Rule 5635(d) through stockholder approval ensures adherence to regulatory standards.

Negatives

• The potential issuance of up to 19,672,130 shares of common stock upon warrant exercise could lead to significant dilution for existing shareholders.
• Failure to obtain stockholder approval for the Private Placement Proposal would require the company to hold additional meetings every 90 days, creating an administrative burden.
• The company is subject to a 90-day lock-up period following the Registration Statement's effective date, restricting certain equity issuances and limiting financing flexibility.

Risks

• Failure to obtain stockholder approval for the Private Placement Proposal could result in non-compliance with Nasdaq Listing Rule 5635(d).
• Significant dilution risk for existing shareholders if the 19,672,130 warrants are fully exercised.
• The company is required to call a meeting every 90 days thereafter seeking Stockholder Approval until it is received or the Warrants are no longer outstanding if approval is not granted at the first meeting.
• Executive officers and directors are subject to lock-up agreements, restricting their ability to sell shares for 90 days following the Registration Statement's effective date.

Future Outlook

The company is required to use commercially reasonable efforts to cause the Registration Statement to be declared effective by the SEC within 60 days following the Private Offering Closing (by approximately January 30, 2026). If stockholder approval for the private placement is not obtained at the first meeting, the company must call a meeting every 90 days thereafter seeking approval until it is received or the warrants are no longer outstanding.

Management Comments

• "Our Board of Directors believes that each of the Private Placement Proposal and the Adjournment Proposal is in the best interests of our Company and our stockholders and unanimously recommends that its stockholders vote FOR each of the Proposals to be presented at the Special Meeting."
• "Our Board of Directors appreciates and encourages your participation in our Special Meeting. Whether or not you plan to attend the Special Meeting, it is important that your shares be represented."

Industry Context

StockSavvy.ai notes that seeking stockholder approval for equity issuances exceeding 20% of outstanding shares is a standard compliance requirement for Nasdaq-listed companies, particularly following private placements. This ensures transparency and adherence to corporate governance best practices, aligning with broader market expectations for investor protection.

Comparison to Industry Standards

• The requirement for stockholder approval under Nasdaq Listing Rule 5635(d) is a standard governance practice for equity issuances exceeding 20% of outstanding shares, similar to rules observed by other major exchanges globally.
• The 7% placement agent fee is within the typical range for private placements of this size, which can vary from 5% to 10% depending on the deal complexity and market conditions, comparable to fees seen in similar transactions for small-cap growth companies.
• The lock-up period for executives and directors for 90 days post-registration statement effectiveness is a common measure to signal commitment and prevent immediate selling pressure, aligning with practices seen in offerings by companies like Teladoc Health or Amwell in the telehealth sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Will vote on significant equity issuance, face potential dilution from warrant exercise, and benefit from the capital raised.
• Warrant Holders: Will receive common stock upon exercise of warrants, subject to stockholder approval.
• Management/Directors: Subject to lock-up agreements, demonstrating commitment to the company.
• Nasdaq: Requires compliance with listing rules for equity issuances.

Next Steps

• Stockholders are to vote on the Private Placement Proposal and the Adjournment Proposal at the Special Meeting on March 2, 2026.
• The company is to use commercially reasonable efforts to cause the Registration Statement to be declared effective by the SEC within 60 days following the Private Offering Closing (by approximately January 30, 2026).
• If stockholder approval is not obtained at the first meeting, the company is required to call a meeting every 90 days thereafter seeking Stockholder Approval until it is received or the Warrants are no longer outstanding.
• Stockholders may submit proposals for the next annual meeting by July 26, 2026 (under Rule 14a-8) or between August 17, 2026, and September 16, 2026 (under company Bylaws).
• Stockholders intending to solicit proxies for director nominees must provide notice by October 16, 2026.

Key Dates

Recommendation

The filing primarily concerns a procedural vote for a completed private placement, which has already brought capital into the company. While the potential for future dilution from warrant exercise exists, the immediate impact is on corporate governance and compliance. A "hold" recommendation reflects the neutral to slightly positive nature of securing capital, balanced by the future dilution risk, without suggesting immediate buying or selling pressure based solely on this proxy statement.

Keywords

VSee Health, Proxy Statement, Special Meeting, Private Placement, Nasdaq Listing Rule 5635(d), Common Stock Issuance, Warrants, Stockholder Vote, Corporate Governance, Capital Raise